Summary

U.S. Veterinary Anti-infectives Market Summary

The U.S. veterinary anti-infectives market was estimated at USD 2.23 billion in 2024 and is projected to reach USD 3.55 billion by 2033, growing at a CAGR of 5.4% from 2025 to 2033. Key factors expected to drive the market include the rise in animal infectious diseases, increasing R&D initiatives, a boost to prudent antibiotic use, development of novel treatments, and growing applications of Artificial Intelligence (AI).

The veterinary anti-infectives market in the U.S. is undergoing a significant transformation, driven by rising concerns over antimicrobial resistance (AMR) in companion animals and livestock. A January 2025 study highlighted in News-Medical underscores how household dogs can harbor and transmit antibiotic-resistant Salmonella, elevating the risk of zoonotic infections. This has raised awareness among veterinarians and pet owners, leading to a growing demand for more targeted and safer anti-infective solutions in the companion animal segment. Veterinary practices are increasingly cautious about the indiscriminate use of broad-spectrum antibiotics, prompting interest in narrow-spectrum drugs, resistance-mitigating therapies, and even preventive care options like probiotics. This trend also fuels the growth of veterinary diagnostics, especially for susceptibility testing that helps guide treatment decisions responsibly.

Innovations to reduce antibiotic reliance further shape the market in the livestock sector. A Penn State study from December 2024 revealed a promising new treatment for mastitis in dairy cows using bacteriophages instead of antibiotics. This breakthrough highlights the expanding market for antibiotic alternatives, including phage therapies, immunomodulators, peptides, and other biologics. Regulatory pressure from the FDA and USDA to curb routine antibiotic use in food-producing animals has increased the adoption of such alternatives, especially among dairy and beef producers. These stakeholders are now seeking effective treatments that comply with antimicrobial stewardship guidelines while maintaining herd health and productivity, thus broadening the veterinary anti-infectives landscape beyond conventional antibiotics.

Meanwhile, the American Veterinary Medical Association (AVMA) has emphasized the importance of communication between veterinarians and animal owners around responsible antibiotic use. This stewardship-led approach is reshaping prescribing behavior across U.S. veterinary practices. As veterinarians prioritize diagnosis-driven treatments and reduce empirical antibiotic use, there is an increasing demand for diagnostics, sensitivity testing, and more refined anti-infective therapies. Pharmaceutical companies are responding by developing precision drugs and educational resources that align with stewardship principles. This shift ensures better health outcomes and drives sustained market demand for innovation in veterinary anti-infectives.

In summary, the U.S. market is propelled by three major forces: the detection of AMR threats in pets, the emergence of non-antibiotic treatments for livestock diseases, and a growing culture of veterinary stewardship. These factors drive market players to diversify product portfolios, invest in R&D for safer alternatives, and develop tools supporting responsible antibiotic use. The result is a market rapidly evolving toward precision, sustainability, and innovation in the fight against antimicrobial resistance.

U.S. Veterinary Anti-infectives Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. veterinary anti-infectives market report based on animal, product, route of administration, type, and distribution channel.

• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Livestock Animal
o Poultry
o Swine
o Cattle
o Sheep & Goats
o Fish
o Others
• Companion Animal
o Dogs
o Cats
o Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Antimicrobial
o Tetracyclines
o Penicillin
o Cephalosporins
o Macrolides
o Quinolones
o Others
• Antifungals
• Antivirals
• Antiparasitic
• Others
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Injectable
• Topical
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• OTC
• Prescription
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital/ Clinic Pharmacy
• Retail Pharmacies
• E-commerce

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.4. Information/Data Analysis
1.5. Market Formulation & Visualization
1.6. Data Validation & Publishing
1.7. Model Details
1.7.1. Commodity flow analysis
1.7.2. Country Market: CAGR Calculation
1.8. List of Secondary Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. U.S. Veterinary Anti-infectives Market Variable Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market
3.1.2. Ancillary Market
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rise in Infectious Diseases Among Animals
3.2.1.2. Growing Research Initiatives
3.2.1.3. Increasing R&D Initiatives
3.2.1.4. Development Of Novel Treatments
3.2.1.5. Increasing Regulatory Approvals
3.2.1.6. Growing Applications of AI
3.2.2. Market Restraint Analysis
3.2.2.1. Drop in Consumption
3.2.2.2. Emerging Drug Resistance
3.2.2.3. Stringent Regulations
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenge Analysis
3.3. U.S. Veterinary Anti-infectives Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitution
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political & Legal landscape
3.3.2.2. Economic and Social landscape
3.3.2.3. Technological landscape
3.3.2.4. Environmental landscape
3.3.3. Regulatory Framework by Key Countries
3.3.4. Estimated Animal Population, by Key Species, by Key Countries, 2021 - 2023
3.3.5. Prevalence of Key Infectious Diseases, by key species, (2024)
3.3.6. COVID-19 Impact Analysis
Chapter 4. U.S. Veterinary Anti-infectives Market: Animal Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Veterinary Anti-infectives Market: Animal Movement Analysis
4.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by animal, 2021 to 2033 (USD Million)
4.4. Livestock Animal
4.4.1. Production Animal Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.2. Poultry
4.4.2.1. Poultry Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3. Swine
4.4.3.1. Swine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.4. Cattle
4.4.4.1. Cattle Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.5. Sheep & Goats
4.4.5.1. Sheep & Goats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.6. Fish
4.4.6.1. Fish Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.7. Others
4.4.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Companion Animal
4.5.1. Companion Animal Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.2. Dogs
4.5.2.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.3. Cats
4.5.3.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.4. Others
4.5.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Veterinary Anti-infectives Market: Product Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Veterinary Anti-infectives Market: Product Movement Analysis
5.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
5.4. Antimicrobials
5.4.1. Antimicrobials Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.2. Cephalosporins
5.4.2.1. Cephalosporins Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.3. Tetracyclines
5.4.3.1. Tetracyclines Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.4. Penicillin
5.4.4.1. Penicillin Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.5. Macrolides
5.4.5.1. Macrolides Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.6. Others (Quinoles, sulfonamides, polymyxins)
5.4.6.1. Others (Quinoles, sulfonamides, polymyxins) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Antifungals
5.5.1. Antifungals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Antivirals
5.6.1. Antivirals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Others
5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. Veterinary Anti-infectives Market: By Route of Administration Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. Veterinary Anti-infectives Market: By Route of Administration Movement Analysis
6.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by route of administration, 2021 to 2033 (USD Million)
6.3.1. Oral
6.3.1.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.2. Injectables
6.3.2.1. Injectables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.3. Others
6.3.3.1. Topical Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. U.S. Veterinary Anti-infectives Market: By Type Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. U.S. Veterinary Anti-infectives Market: By Type Movement Analysis
7.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by type, 2021 to 2033 (USD Million)
7.3.1. OTC
7.3.1.1. OTC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.2. Prescription
7.3.2.1. Prescription Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Veterinary Anti-infectives Market: By Distribution Channel Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. U.S. Veterinary Anti-infectives Market: By Distribution Channel Movement Analysis
8.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
8.3.1. Hospital/Clinic Pharmacy
8.3.1.1. Retail Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.2. Retail Pharmacies
8.3.2.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.3. E-commerce
8.3.3.1. E-commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Market Participant Categorization
9.2. Company Market Position Analysis/ Heap Map Analysis
9.3. Company Profiles
9.3.1. Zoetis
9.3.1.1. Participant’s Overview
9.3.1.2. Financial Performance
9.3.1.3. Product Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Boehringer Ingelheim
9.3.2.1. Participant’s Overview
9.3.2.2. Financial Performance
9.3.2.3. Product Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. Merck & Co. Inc.
9.3.3.1. Participant’s Overview
9.3.3.2. Financial Performance
9.3.3.3. Product Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. Dechra Pharmaceuticals Plc.
9.3.4.1. Participant’s Overview
9.3.4.2. Financial Performance
9.3.4.3. Product Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. Elanco Animal Health
9.3.5.1. Participant’s Overview
9.3.5.2. Financial Performance
9.3.5.3. Product Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Ceva Sante Animale
9.3.6.1. Participant’s Overview
9.3.6.2. Financial Performance
9.3.6.3. Product Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Virbac
9.3.7.1. Participant’s Overview
9.3.7.2. Financial Performance
9.3.7.3. Product Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. Biogenesis Bago
9.3.8.1. Participant’s Overview
9.3.8.2. Financial Performance
9.3.8.3. Product Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. Vetoquinol
9.3.9.1. Participant’s Overview
9.3.9.2. Financial Performance
9.3.9.3. Product Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. Calier
9.3.10.1. Participant’s Overview
9.3.10.2. Financial Performance
9.3.10.3. Product Benchmarking
9.3.10.4. Strategic Initiatives
9.3.11. Norbrook Laboratories
9.3.11.1. Participant’s Overview
9.3.11.2. Financial Performance
9.3.11.3. Product Benchmarking
9.3.11.4. Strategic Initiatives
9.4. Strategy Mapping
9.4.1. Mergers & Acquisitions
9.4.2. Partnerships & Collaborations
9.4.3. Expansion
9.4.4. Product launch
9.4.5. Product Approval
9.4.6. Others
9.5. List of Key Companies
9.5.1. List of Manufacturers
9.5.2. List of Distributors